Magazine article Clinical Psychiatry News

OROS Methylphenidate Lifts ADHD Symptoms

Magazine article Clinical Psychiatry News

OROS Methylphenidate Lifts ADHD Symptoms

Article excerpt

VIENNA -- Osmotic-release oral system methylphenidate proved effective in the Long-Acting Methylphenidate in Adult ADHD trial, Dr. Rossella Medori reported at the annual congress of the European College of Neuropsychopharmacology.

Dose-related improvements in the core symptoms of inattention and hyperactivity/impulsivity within attention-deficit/hyperactivity disorder were documented in this large trial across a range from 18 to 72 mg/day, added Dr. Medori of Janssen-Cilag, Neuss, Germany.

The trial, abbreviated LAMDA, was a double-blind multicenter European clinical trial in which 401 adults with ADHD, mean age 34 years, were randomized to 5 weeks of osmotic-release oral system (OROS) long-acting methylphenidate at 18, 36, or 72 mg once daily or to placebo.

After 5 weeks, a 30% or larger reduction in Conners' Adult ADHD Rating Scale total score, compared with baseline, was found in 60% of patients on the long-acting methylphenidate at 72 mg/day, 49% on 36 mg/day, 51% on 18 mg/day, vs. 27% on placebo.

Patients indicated they experienced significantly less functional impairment of work, family, and social life while on the medication as reflected in improved scores on the self-rated Sheehan Disability Scale.

In addition, the patients reported significant and dose-dependent improvements in ADHD symptoms while on the medication, as indicated by greater reductions from baseline than with placebo on the Conners' Adult ADHD Rating Scale self-report short version.

These are important findings, because patients' opinions about the efficacy of their ADHD treatment are an important factor in medication adherence, Dr. Medori observed.

A total of 3% of subjects withdrew from the study because of an adverse event.

The most common adverse event associated with long-acting methylphenidate was a dose-dependent increased rate of diminished appetite, reported by an average of 25% on methylphenidate and 7% on placebo. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.